Rare leptin disorder patients gain access to experimental drug
NCT ID NCT04710056
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides expanded access to REGN4461 (mibavademab) for people with rare diseases caused by deficient leptin signaling, such as generalized lipodystrophy and monogenic obesity. The drug aims to help control metabolic issues linked to these conditions. Participants receive the medication outside of a formal clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN4461 (mibavademab)
What this could lead to
If it works, this could help control metabolic complications in people with rare leptin-signaling disorders.
What could go wrong
This is an expanded access program, not a formal trial, so evidence on safety and effectiveness is limited. Benefits may vary and risks are not fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••